Physician profile
Geoffrey S Walker
NPI 1306890058
$20,670.96
in general payments reported to CMS, 2019-2025
11 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2022: $144 · 2023: $60.43 · 2024: $482 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $1,523 · Travel and Lodging: $853 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,962.05 |
| Food and Beverage | $1,523.22 |
| Travel and Lodging | $853.21 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $15,562.05 | 2025 | Defencath |
| Fresenius USA Marketing, INC. | $4,009.39 | 2024-2025 | Nxstage System One |
| Nxstage Medical, INC. | $573.82 | 2019-2025 | Nxstage System One, Liberty Select Cycler, Pureflow Sl |
| Akebia Therapeutics INC | $158.29 | 2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $131.36 | 2023-2024 | Xphozah 30 Mg, Ibsrela |
| Amgen INC. | $97.00 | 2019 | |
| Baxter Healthcare | $37.39 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.16 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $28.99 | 2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.08 | 2024 | Jardiance |
| Vertex Pharmaceuticals Incorporated | $17.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.